Pune, India -- (SBWire) -- 02/28/2019 --The increase in number of aesthetic surgeries such as breast augmentation, nose reshaping, eyelid surgery, liposuction and neck lift performed in the United States due to the growing obsession among Americans with beauty is fueling the market. The number of cosmetic procedures performed in the United States gradually increased by 115 percent from 2000 to 2015 due to which there was an increase in the production of biological skin substitutes. This growing trend among Americans to change their faces and get rid of extra fat to look more youthful is driving the market for skin substitutes in the U.S.
However, the limitation of the commercially available skin substitutes such as the inability to reproduce skin appendages, lack of capability to replace the lost tissue, particularly the dermis of the skin is preventing the market from growing. Reduced vascularization, scarring, failure to integrate, poor mechanical integrity, and immune rejection are some other limitations. Skin substitutes when placed on wounds need to acquire blood supply promptly for their long-term survival and integration into host tissue. Their inability to re-vascularize rapidly results in cell death and ultimate sloughing away from the host. Although some of the commercially available substitutes undergo angiogenesis, the extent of vascularization offered by them is generally insufficient and has to be improved.
For Sample Copy:
https://www.absolutemarketsinsights.com/request_sample.php?id=122
Skin Substitutes Market is Fragmented Due to the Presence of Many Small and Medium Scale artificial Substitutes Producing Companies
Market participants include Stratatech a Mallinckrodt, PolyNovo North America LLC, Organogenesis Inc., Mölnlycke Health Care AB, Medtronic (Covidien), Integra Life Sciences Corporation, Genzyme Corporation, Cook Biotech, Inc., BSN Medical, C. R. Bard, Inc., AMARANTUS BIOSCIENCE HOLDINGS, INC., AlloSource, Advanced Tissue, Acelity L.P. Inc. (KCI- Kinetic Concepts Inc.), Soluble Systems, LLC (Alliqua BioMedical, Inc.), Smith & Nephew plc., Shire Regenerative Medicine, Inc. (formerly Advanced BioHealing, Inc.) and Tissue Regenix Group Plc amongst others. The U.K based pharmaceutical company Mallinckrodt acquired Stratatech corp., in August 2016. to increase its product offering in the skin substitutes market. Stratatech is a privately held regenerative medicine company focused on the development of unique and proprietary skin substitute products.
The Usage of Skin Substitutes in Treatment of Diabetic Foot Ulcers is increasing
Diabetic foot ulcer is a major condition that occurs in people suffering from diabetes mellitus. Treatments of diabetic foot ulcers includes blood sugar control, removal of dead tissue from the wound and wound dressings. Despite the current treatments available for foot ulcers, not all the ulcers can be completely healed by medicines or sugar control and they need a skin substitute for repair of affected area's tissue. Skin substitutes are being used after dead tissue removal from the foot so that the wounds get healed fast.
Avail Discount at:
https://www.absolutemarketsinsights.com/ask_for_discount.php?id=122
Biological Skin Substitutes Obtained from Biological Sources is one of The Major Product Type
The biological skin substitutes that mainly include living tissues obtained from biological sources such as plants and animals are being preferred by many due to their intact extracellular matrix structure that allows for effective and scar-free wound healing, which is not provided by any other substitute.
Skin Substitutes Market – By Application
- Burn Injury
- Diabetic Foot Ulcers
- Chronic Wounds
- Others (Vascular Ulcers, Plastic Surgery, Etc.)
Skin Substitutes Market – By Product Type
- Synthetic Skin Substitute
- Biosynthetic Skin Substitute
- Biological Skin Substitute
- Xenograft
Market by End User
- Hospitals
- Other Healthcare Facilities
For More Information:
https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=122
